Introduction
Kaposi's sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus-8, is a member of the g-herpesvirus family, which includes the Epstein-Barr virus and the herpesvirus saimiri. KSHV was initially identified in KS lesions using representational difference analysis, a PCR-based subtractive hybridization method (Chang et al., 1994; Moore and Chang, 1995) . KSHV is involved in the pathogenesis of all types of KS, including classical, AIDS-associated, endemic, and transplantrelated KS (Boshoff et al., 1995; Huang et al., 1995; Memar et al., 1995; Moore and Chang, 1995; Alkan et al., 1997) . It also plays a contributory role in two B-cell malignancies, primary effusion lymphoma (PEL or body cavity-based lymphoma) and a subset of multicentric Castleman's disease (Cesarman et al., 1995; Soulier et al., 1995) . Although many viral genes, whose products transform the KSHV-infected cells or modulate host immune responses, are identified in the KSHV genome, the exact mechanism of oncogenesis induced by KSHV infection is still unknown.
KSHV open reading frame K8 encodes an early viral protein that is activated during lytic replication of KSHV Sun et al., 1999) . K-bZIP, the major product of open reading frame K8, is a transcription factor consisting of 237 amino acids with a prototypic basic region-leucine zipper domain at the carboxyl-terminus region. Recent data showed that K-bZIP homodimerized in the cytoplasm and was transported to the nucleus (Hwang et al., 2001; Portes-Sentis et al., 2001) . K-bZIP interacts and colocalizes with the transcriptional coactivator CREBbinding protein (CBP) (Hwang et al., 2001) . Interaction is dependent on the basic region of K-bZIP and the cysteine/histidine-rich domains 3 of CBP (Hwang et al., 2001) . CBP and its homologue p300 act as adaptors, linking transcription factors to the basal transcriptional apparatus such as TFIIB and RNA polymerase II in the transcriptional initiation complex (Chan and La Thangue, 2001 ). CBP/p300 has histone acetyltransferase activity that loosens the condensed structure of chromatin and promotes the accessibility of transactivation machinery to target DNA (Chan and La Thangue, 2001) . Interaction between K-bZIP and CBP, which might lead to competition between K-bZIP and other transcription factors for limited amounts of CBP, modulates CBP-mediated transcription of promoters including the AP-1-and nuclear factor (NF)-kBresponsive elements (Hwang et al., 2001) . K-bZIP also represses the transcriptional activity of p53, which is required for apoptosis of the host cell, through direct interaction with p53 (Park et al., 2000) . These data imply that K-bZIP is involved in KSHV-driven transcriptional modulation.
Transforming growth factor b (TGF-b) is one of the best-characterized members of growth-inhibitory factors. TGF-b can inhibit the growth of various cell types including epithelial cells, vascular endothelial cells, hematopoietic cells, and immune lymphocytes (Sporn and Roberts, 1990; Miyazono et al., 1994; Blobe et al., 2000) . In contrast, most malignant cells are refractory to TGF-b-induced growth arrest. Since proliferation and differentiation of cells are tightly regulated by a delicate balance of growth factors and growth-inhibitory factors, loss of sensitivity to TGF-b may link to tumor progression. A class of transcription factors, called the Smad proteins, mediates the signaling of the TGF-b intracellular pathway (Zhang et al., 1996) . Responding to TGF-b binding, type II TGF-b receptor (TbRII), an active type II receptor kinase, phosphorylates and activates type I TGF-b receptor (TbRI) (Wrana et al., 1994; Chen and Weinberg, 1995) . The activated TbRI then interacts with an adaptor molecule known as Smad anchor for receptor activation (Tsukazaki et al., 1998) , which recruits Smad2 and Smad3 to the plasma membrane. Smad2 and Smad3 are phosphorylated by TbRI, and then form a heterodimeric complex with Smad4 (Massague, 1998) . The Smad complex translocates into the nucleus where it binds to the TGF-bresponsive promoter either directly through the Smad-binding elements containing a CAGA box within plasminogen activator inhibitor (PAI)-1 promoter (Dennler et al., 1998; Song et al., 1998; Zawel et al., 1998) , or in conjunction with other sequence-specific DNA-binding proteins such as those in the FAST family (Chen et al., 1996 (Chen et al., , 1997 Labbe et al., 1998; Zhou et al., 1998) . Activin, which is an important player in the mammalian endocrine reproductive axis, is one of the members of TGF-b superfamily. Like TGF-b, activin assembles a receptor complex that activates Smads and induces the assembly of a DNA-protein complex that is composed of Smad2, Smad4, and a member of the FAST family. The complex then stimulates transcription of the promoters containing activin response element (ARE) sites (Chen et al., 1997) . Smad2, Smad3, and Smad4 physically interact with the transcriptional coactivator CBP and its homologue p300 and enhance transcriptional activation by TGF-b (Feng et al., 1998; Janknecht et al., 1998; Pouponnot et al., 1998; Shen et al., 1998; Topper et al., 1998) . Since both K-bZIP and Smad proteins interact with CBP, we explored the role of K-bZIP in the regulation of TGF-b signaling to understand the carcinogenic mechanism of KSHV.
Results

K-bZIP impairs TGF-b growth-inhibitory effect
To determine whether K-bZIP could affect the growthinhibitory effect of TGF-b, we established Mv1Lu cell lines (mink lung cell line) stably expressing K-bZIP ( Figure 1a ). When cultured in the absence of TGF-b, all of these clones showed similar proliferative abilities (data not shown). In the presence of TGF-b, proliferation of Mv1Lu cells as well as the control Mv1Lu cell line, referred to as neo-1, transfected with empty vector, was inhibited by approximately 70%. In contrast, the proliferation of K-bZIP-expressing cells was inhibited more weakly in the presence of the same amount of TGF-b (Figure 1b) . These data indicate that K-bZIP impairs the growth-inhibitory effect of TGF-b.
K-bZIP represses TGF-b-induced transcriptional activation of the target promoter
We examined the effect of K-bZIP on TGF-b-induced transcriptional response using cotransfection assays. HepG2 cells (human hepatoma cell line) were transfected with the TGF-b-responsive p3TP-Lux reporter plasmid consisting of the human PAI-1 promoter with a luciferase reporter gene (Wrana et al., 1994) . When p3TP-Lux alone was transfected in HepG2 cells, a significant increase in luciferase activity was observed in (Figure 2a ). We performed these experiments using Mv1Lu cells, and similar results were obtained (Figure 2b ). These results demonstrate that K-bZIP represses TGF-b-induced transcriptional activation of the target promoter.
K-bZIP inhibits transcriptional activation induced by the constitutively active TbRI
To determine the point within the pathway at which this blockade occurs, we examined receptor-dependent transcriptional activation using TbRI-T204D, a constitutively active TGF-b type I kinase receptor. TbRI-T204D-induced transcription was significantly reduced by K-bZIP (Figure 3 ), indicating that K-bZIP blocks the molecules downstream of TbRI. Because TbRI-WT, the wild-type TGF-b type I receptor, could not signal in the absence of ligand, elevation of luciferase activity by TbRI-WT did not occur with the p3TP-Lux construct ( Figure 3 ).
K-bZIP represses Smad-dependent transcriptional activation
To examine the effects of K-bZIP on transcriptional activity of Smads, which are signal transduction molecules downstream of TbRI, we assayed the effects of K-bZIP on transcriptional responses in the presence of various Smad proteins or Smad heterodimeric complexes. K-bZIP inhibited Smad2-, Smad3-, Smad4-, or a combination of Smad2 and Smad4 (Smad2/4)-or Smad3 and Smad4 (Smad3/4)-induced transcriptional activation of p3TP-Lux (Figure 4a ). TGF-b enhanced Smad-induced transactivation, and this transcriptional activation was also inhibited by K-bZIP ( Figure 4a ). In addition to an analysis of the p3TP-Lux construct, we also examined the induction of the Smad-responsive ARE-Lux construct containing ARE sites from the Xenopus Mix.2 gene. Cotransfection of K-bZIP and ARE-Lux into the HepG2 cells markedly inhibited the transcriptional activation of the ARE-Lux that was mediated by the complex of Smad2, Smad4, and FAST-1 (Figure 4b ). K-bZIP inhibited this transcriptional activation even after TGF-b stimulation ( Figure 4b ). Because HepG2 cells do not have endogenous FAST activity, overexpression of Smad2 and Smad4 alone could not stimulate the ARE-Lux reporter construct even in the presence of TGF-b (Figure 4b ). In the presence of overexpressed FAST-1, the reporter gene activity was induced by TGF-b, which may be explained by an activation mediated by endogenous Smad2 and Smad4. These results demonstrate that K-bZIP represses Smaddependent transcriptional activation.
Lack of interaction of K-bZIP with Smad proteins
To identify the target through which K-bZIP represses TGF-b signaling, we tested whether K-bZIP could interact with Smad proteins. We transfected Smad2, Smad3, or Smad4 into 293T cells (human kidney cell line) together with K-bZIP. We did not detect coimmunoprecipitation of K-bZIP with any of the Smad proteins, even though these proteins were expressed in 293T cells and immunoprecipitated ( Figure 5a and data not shown). This result indicates that K-bZIP does not interact with any of the Smad proteins.
K-bZIP inhibits neither phosphorylation of Smad2 nor formation of heterodimers containing Smad2 and Smad4
To determine whether phosphorylation of Smad2 following activation of TbRI is affected by K-bZIP, 
CBP-binding domain of K-bZIP is involved in the suppression of Smad transactivation function
To address the mechanism whereby K-bZIP suppresses the transcriptional activation of the TGF-b signal transduction pathway, we tested two previously characterized K-bZIP deletion mutants, carboxyl-terminal deletion mutant K-bZIP(1-115) and amino-terminal deletion mutant , that do not contain the basic region (amino acids 116-189), which is the CBP-binding site of K-bZIP (Hwang et al., 2001) . Although wild-type K-bZIP inhibited the TGF-b-as well as Smad3-induced transcriptional activity in a dosedependent manner, K-bZIP deletion mutants could not alter the transactivation induced by TGF-b (Figure 7a ) nor by Smad3 (Figure 7b ), demonstrating that the CBPbinding domain of K-bZIP is involved in the suppression of Smad transactivation function.
Coexpression of CBP restores the inhibition of Smad3-mediated transactivation by K-bZIP
To emphasize this finding, increasing concentrations of the CBP expression plasmid were cotransfected with a p3TP-Lux reporter plasmid, together with K-bZIP and (Figure 8a ). These results demonstrate that inhibition of Smad3 function by K-bZIP is dependent on the concentration of CBP.
K-bZIP represses TGF-b signaling by competing with Smad3 for binding to CBP
To investigate whether K-bZIP is able to interfere with the recruitment of CBP to Smad, we assessed the interaction between endogenous Smad3 and CBP in HepG2 cells in the presence or absence of K-bZIP. Transfected cells were incubated in the presence or absence of TGF-b. Immunoprecipitation of endogenous CBP, followed by Western blotting with an anti-Smad3 antibody, showed that the level of Smad3, which was coimmunoprecipitated with CBP, was increased by TGF-b stimulation and it was decreased by overexpression of K-bZIP to that without TGF-b stimulation (Figure 8b ). This result indicates that K-bZIP represses TGF-b signaling by competing with Smad3 for binding to CBP.
Discussion
The ability of some viral proteins to transform cells is closely associated with their ability to interact with CBP/p300. Adenovirus E1A blocks TGF-b responses through its interaction with CBP/p300, thereby preventing the transcriptional activity of the Smad proteins (Datto et al., 1997; Nishihara et al., 1998 Nishihara et al., , 1999 . Interaction of Tax, encoded by the human T-cell leukemia virus type 1, with CBP/p300 also contributes to its oncogenic activity (Bex et al., 1998; Harrod et al., 1998) . We previously demonstrated that Tax represses the Smad-dependent TGF-b signaling pathway by competing with the Smads for association with CBP/ p300 (Mori et al., 2001) . Since K-bZIP of KSHV interacts with CBP (Hwang et al., 2001) , we explored the influence of K-bZIP in the regulation of TGF-b signaling to investigate the carcinogenic mechanism of KSHV. In this report, K-bZIP is identified as a new and important player in the oncogenesis of KSHV-related tumor. We conclude that K-bZIP is an inactivator of TGF-b/Smad-mediated transcriptional activation and repression of cell growth, and that repression of TGF-b signaling by K-bZIP depends on the competition with Smad for binding to CBP. The mechanism of the repression of TGF-b signaling by K-bZIP may involve interfering with the recruitment of a limiting amount of intracellular CBP to Smad. Since Smad proteins and K-bZIP bind to distinct regions of CBP (Feng et al., 1998; Janknecht et al., 1998; Nishihara et al., 1998; Topper et al., 1998; Hwang et al., 2001) , competition between K-bZIP and the Smads in binding with CBP initially appeared unlikely. However, this competition does not require an identical or overlapping binding site on the coactivator and has been described for several cellular pathways, such as the nuclear receptor and AP-1, p53 and E2F, NF-kB and p53, NF-kB and nuclear receptors, Jak-Stat and AP-1 pathways (Kamei et al., 1996; Horvai et al., 1997; Lee et al., 1998; Sheppard et al., 1998; Wadgaonkar et al., 1999) . There might be other places on CBP where both K-bZIP and Smad proteins interact, and K-bZIP may inactivate Smad proteins by specifically competing for Smad-CBP interaction.
K-bZIP-induced repression in TGF-b signaling likely provides the optimal conditions for tumorigenesis of the KSHV-infected cells. Significantly, we showed that this inhibition was sufficient to disrupt the growth-inhibitory effect of TGF-b. CBP/p300 is an integrator based on its role in determining the relative transcriptional responses of a specific target gene in the face of activation of multiple signal transduction pathways such as the signals of diverse growth factors, hormones, and intracellular ligands that combinatorially modulate homeostasis and proliferation. In addition to inhibiting TGF-b signaling, K-bZIP may also have the capacity to modulate other CBP-dependent signaling pathways. The involvement of other signaling pathways that are modulated by K-bZIP should also be explored as our data did not preclude the involvement of other signaling components.
The majority of endothelial spindle cells in KS are latently infected (Staskus et al., 1997) , implicating the EMSA was carried out with 3 Â CAGA probe and nuclear extracts from 293T cells transfected with indicated combinations of Flag-Smad3, Myc-Smad4, HA-K-bZIP, and TbRI-T204D-HA. Where indicated, 100-fold excesses of nonradiolabeled oligonucleotides were added as competitors, including the wild-type (W) and mutated (M) CAGA sequences (lanes 6 and 7). EMSA supershifts using antibodies to Flag, Myc, Smad3, and HA were carried out (lanes 8-11 and 13-15). (b) Effect of K-bZIP on the DNA-binding activity of endogenous Smad3. HepG2 cells were transfected with either empty vector or HA-K-bZIP. After treatment with TGF-b, nuclear extracts were prepared and Smad binding to a 3 Â CAGA probe was examined. Where indicated, 100-fold excesses of nonradiolabeled oligonucleotides were added as competitors, including the wild-type (W) and mutated (M) CAGA sequences (lanes 5 and 6). EMSA supershifts using antibodies to Smad3 (lane 7) were carried out Inhibition of TGF-b signaling by KSHV K-bZIP M Tomita et al direct involvement of latent genes in the transformation of KS cells. Since K-bZIP is expressed during lytic replication of KSHV, it seems unlikely that K-bZIP promotes the survival of KSHV-infected cells. However, many viral genes that play roles in angiogenesis and inflammation, which are key features of KS histology, are expressed predominantly in the lytic cycle (Arvanitakis et al., 1997; Boshoff et al., 1997; Boshoff, 1998) . Moreover, immunohistochemical and Western blotting analysis using specific antibodies revealed that K-bZIP protein can be detected in KS spindle cells and primary PEL cells (Katano et al., 2000) . Further experiments will be needed to investigate whether K-bZIP can promote the survival of endothelial cells or B lymphocytes endogenously infected with KSHV by suppressing TGF-b action.
Materials and methods
Plasmid constructions
The expression plasmids for K-bZIP (HA-K-bZIP) and the K-bZIP-derived mutants (K-bZIP(1-115) and K-bZIP(190-237)), which fuse the nuclear localization signal and the HA tag onto the amino-terminal region of a cloned protein, have previously been described (Hwang et al., 2001 (Wrana et al., 1994) .
Cell culture
HepG2 (human hepatoma cell line), Mv1Lu (mink lung cell line), and 293T (human kidney cell line) were maintained in DMEM supplemented with 10% heat-inactivated FBS, 50 U/ml penicillin, and 50 mg/ml streptomycin (Invitrogen, Carlsbad, CA, USA) in a humidified incubator under 5% CO 2 .
Transfection and luciferase assay
293T cells were transfected with the indicated constructs using a calcium phosphate transfection method. HepG2 and Mv1Lu cells were transfected using Lipofectamine (Invitrogen). Luciferase assays were performed as described previously (Mori et al., 2001) . In brief, HepG2 and Mv1Lu cells were transiently transfected with the indicated effecter plasmids, luciferase reporter constructs (0.1 mg), and the internal control of transfection efficiency, phRL-TK (0.1 mg). The cells were harvested 24 h after transfection. For TGF-b-inducible luciferase reporter assays, cells were incubated for additional 24 h in the absence or presence of 5 ng/ml TGF-b. Luciferase assays were performed by using the Dual-Luciferase Reporter System (Promega, Madison, WI, USA), in which relative luciferase activities were calculated by normalizing transfection efficiency according to the Renilla luciferase activities.
Antibodies
The following antibodies were used: anti-c-Myc (9E10; SigmaAldrich, St Louis, MO, USA), anti-HA (Y-11; Santa Cruz, CA, USA), anti-Flag (M2; Sigma-Aldrich), anti-Smad2/3 (BD Transduction Laboratories, San Jose, CA, USA), antiphospho-Smad2 (Cell Signaling Technology, Beverly, MA, USA), anti-CBP (Santa Cruz), and anti-actin (NeoMarkers, Fremont, CA, USA). Horseradish peroxidase-conjugated antimouse and anti-rabbit IgG antibodies for Western blotting were purchased from Amersham Biosciences (Piscataway, NJ, USA).
Western blot analysis
Cells were lysed in SDS sample buffer (62.5 mM Tris-HCl pH 6.8, 2% SDS, 10% glycerol, 6% 2-ME, and 0.01% bromophenol blue). The lysates were resolved by electrophoresis on polyacrylamide gels and electroblotted onto PVDF membranes (Millipore, Billerica, MA, USA). Membranes were incubated with the appropriate primary antibody as indicated in the figures (Figures 1a, 5 , and 8b) overnight at 41C. The next day, the blots were exposed to the appropriate secondary antibody conjugated with horseradish peroxidase for 1 h at room temperature. The reaction product was visualized using enhanced chemiluminescence reagent according to the manufacturer's instructions (Amersham Biosciences).
Generation of Mv1Lu cell lines expressing K-bZIP
To generate stable Mv1Lu cell lines overexpressing K-bZIP, cells were transfected with either empty vector or HA-K-bZIP together with an expression plasmid containing a NEO cassette. Cells were selected with 800 mg/ml G418 (Nakarai Tesque, Kyoto, Japan) for 2-3 weeks and then cloned. The expression level of K-bZIP protein was confirmed by Western blotting using an anti-HA antibody.
Assays for cellular proliferation
Cell proliferation was measured by a viability and nonradioactive cell proliferation assay system known as the WST-8 assay based on the MTT assay (Cell Counting Kit-8, Wako Chemical, Osaka, Japan). Cells were plated in 96-well microtiter plates and incubated with 0.1 ng/ml TGF-b in DMEM containing 0.2% FBS for 48 h. Then, 5 ml of Cell Counting Kit-8 solution (5 mM WST-8, 0.2 mM 1-methoxy-5-methylphenazinium methylsulfate, and 150 mM NaCl) was added to each well. Cell proliferation was determined by the OD 450 level after 4 h incubation.
Immunoprecipitation analysis
293T or HepG2 cells were transiently transfected with the indicated constructs. Cell lysates were made approximately 24 h following either transfection or treatment with 5 ng/ml TGF-b in a TNTE buffer (20 mM Tris-HCl pH 7.5, 1 mM EDTA, 150 mM NaCl, 0.5% Triton X-100, 50 mM sodium fluoride, 10 mM sodium orthovanadate, 10 mM sodium pyrophosphate, and 20 mM phenylmethylsulfonyl fluoride) containing a protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany). An equal amount of lysate was incubated with the indicated antibodies at 41C for 1 h, followed by incubation with protein G-immobilized on agarose (Sigma-Aldrich) at 41C for 1 h. After washing four times with TNTE buffer, immunoprecipitates were eluted in SDS sample buffer. The whole-cell lysates or immunoprecipitates were probed with appropriate antibodies as indicated in the figures.
Preparation of nuclear extracts
Nuclear extracts were prepared as described previously . In brief, cells were solubilized in 200 ml lysis buffer A1 (10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, and 2 mM AEBSF). After incubating for 10 min on ice, 200 ml cold lysis buffer A2 (A1 with 0.6% NP-40 at final concentration) was added. Nuclei were prepared by microcentrifugation at 1000 rpm for 5 min at 41C. The nuclear pellet was suspended in 75 ml buffer C (20 mM HEPES pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 2 mM AEBSF, 33 mg/ml aprotinin, 10 mg/ml leupeptin, 10 mg/ml E-64, and 10 mg/ml pepstatin A) and incubated for 30 min on ice with brief mixing. The nuclear extract was microcentrifuged at 15 000 rpm for 15 min at 41C. The concentration of the cell extracts was determined using a Coomassie blue-based protein assay (Bio-Rad, Hercules, CA, USA).
EMSA EMSA was performed as described previously (Mori et al., 2003) . In brief, the 3 Â CAGA probe was labeled with [a-32 P]dCTP and [a-32 P]dATP using the Klenow enzyme. Nuclear extracts (5 mg) were preincubated in a binding buffer containing 1 mg poly-deoxy-inosininc-deoxy-cytidylic acid (Pharmacia), followed by addition of the radiolabeled probe. These mixtures were incubated for 15 min at room temperature.
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